Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is a biopharmaceutical company that specializes in the discovery, development, and commercialization of RNA interference (RNAi) therapeutics. The company focuses on addressing rare genetic disorders and diseases affecting the cardiovascular, hepatic, and central nervous systems. Its marketed products include ONPATTRO, which treats hereditary transthyretin-mediated amyloidosis, and GIVLAARI, aimed at adults with acute hepatic porphyria. Additionally, Alnylam is advancing several investigational therapies, such as givosiran for acute hepatic porphyria, lumasiran for primary hyperoxaluria type 1, and vutrisiran for transthyretin amyloidosis. The company has established strategic alliances with organizations such as Sanofi Genzyme and Regeneron Pharmaceuticals to further its RNAi therapeutic developments. Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam Pharmaceuticals is recognized as a leader in the RNAi therapeutic field, leveraging Nobel Prize-winning science to create innovative medicines for severe diseases.

Jeff Poulton

CFO

1 past transactions

Ribopharma AG

Acquisition in 2003
Development and marketing of SIRPLEX, a pharmaceutical substance based on double-stranded RNA.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.